MX2021002994A - Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1). - Google Patents
Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1).Info
- Publication number
- MX2021002994A MX2021002994A MX2021002994A MX2021002994A MX2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A
- Authority
- MX
- Mexico
- Prior art keywords
- alopecia
- prevention
- pai
- inhibitors
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731076P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/050890 WO2020056191A1 (en) | 2018-09-13 | 2019-09-12 | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002994A true MX2021002994A (es) | 2021-07-15 |
Family
ID=68073184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002994A MX2021002994A (es) | 2018-09-13 | 2019-09-12 | Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1). |
| MX2025003991A MX2025003991A (es) | 2018-09-13 | 2021-03-12 | Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025003991A MX2025003991A (es) | 2018-09-13 | 2021-03-12 | Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220079911A1 (https=) |
| EP (1) | EP3849540A1 (https=) |
| JP (2) | JP7777448B2 (https=) |
| KR (2) | KR20250161056A (https=) |
| CN (2) | CN113056269A (https=) |
| AU (1) | AU2019339488B2 (https=) |
| BR (1) | BR112021004550A2 (https=) |
| CA (1) | CA3112549A1 (https=) |
| IL (1) | IL281451A (https=) |
| MX (2) | MX2021002994A (https=) |
| SG (1) | SG11202102479TA (https=) |
| WO (1) | WO2020056191A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017360346B2 (en) | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| AU2024344613A1 (en) * | 2023-09-18 | 2026-04-23 | Eirion Therapeutics, Inc. | Topical compositions and uses of pai-1 inhibitors |
| CN117919248B (zh) * | 2024-03-22 | 2024-06-04 | 四川兴泰普乐医疗科技有限公司 | 一种可注射生发组合物及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US6461596B1 (en) * | 1997-02-18 | 2002-10-08 | Andrea Taylor | Composition and method for promoting hair growth |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| US20060058369A1 (en) * | 2002-02-19 | 2006-03-16 | Vanderbilt University | Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors |
| WO2003071267A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| EP1509236A4 (en) * | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS |
| BRPI0619134B8 (pt) | 2005-12-01 | 2021-05-25 | Univ Massachusetts Lowell | nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão |
| EP2015773A4 (en) | 2006-04-27 | 2010-05-05 | Anterios Inc | EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS |
| CA2691214A1 (en) * | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2008070538A2 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
| WO2009123241A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター－１阻害剤 |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| MX379265B (es) | 2008-06-26 | 2025-03-11 | Anterios Inc | Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel. |
| US20110112041A1 (en) * | 2009-10-01 | 2011-05-12 | Baylor Research Institute | Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease |
| KR20140005998A (ko) | 2011-01-24 | 2014-01-15 | 안테리오스, 인코퍼레이티드 | 나노입자 조성물, 이의 제형, 및 그의 용도 |
| EP2667854B1 (en) | 2011-01-24 | 2019-01-16 | Anterios, Inc. | Nanoparticle compositions |
| WO2013096026A1 (en) | 2011-12-21 | 2013-06-27 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
| CN103479627A (zh) * | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
| CN115998740A (zh) * | 2014-10-29 | 2023-04-25 | 萨姆森临床私人有限公司 | 毛发过度脱落的检测和治疗 |
| US20160144001A1 (en) * | 2014-11-21 | 2016-05-26 | Northwestern University | Methods and compositions for modulating fgf23 levels |
-
2019
- 2019-09-12 CA CA3112549A patent/CA3112549A1/en active Pending
- 2019-09-12 CN CN201980074634.2A patent/CN113056269A/zh active Pending
- 2019-09-12 KR KR1020257037247A patent/KR20250161056A/ko active Pending
- 2019-09-12 BR BR112021004550-3A patent/BR112021004550A2/pt unknown
- 2019-09-12 WO PCT/US2019/050890 patent/WO2020056191A1/en not_active Ceased
- 2019-09-12 AU AU2019339488A patent/AU2019339488B2/en active Active
- 2019-09-12 CN CN202511050773.5A patent/CN120899921A/zh active Pending
- 2019-09-12 KR KR1020217010850A patent/KR102884804B1/ko active Active
- 2019-09-12 EP EP19779255.9A patent/EP3849540A1/en active Pending
- 2019-09-12 US US17/274,937 patent/US20220079911A1/en active Pending
- 2019-09-12 JP JP2021514400A patent/JP7777448B2/ja active Active
- 2019-09-12 SG SG11202102479TA patent/SG11202102479TA/en unknown
- 2019-09-12 MX MX2021002994A patent/MX2021002994A/es unknown
-
2021
- 2021-03-11 IL IL281451A patent/IL281451A/en unknown
- 2021-03-12 MX MX2025003991A patent/MX2025003991A/es unknown
-
2025
- 2025-05-28 JP JP2025088639A patent/JP2025138639A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220079911A1 (en) | 2022-03-17 |
| MX2025003991A (es) | 2025-05-02 |
| KR102884804B1 (ko) | 2025-11-12 |
| CN113056269A (zh) | 2021-06-29 |
| IL281451A (en) | 2021-04-29 |
| JP2022500452A (ja) | 2022-01-04 |
| WO2020056191A1 (en) | 2020-03-19 |
| CA3112549A1 (en) | 2020-03-19 |
| KR20250161056A (ko) | 2025-11-14 |
| KR20210057140A (ko) | 2021-05-20 |
| CN120899921A (zh) | 2025-11-07 |
| JP7777448B2 (ja) | 2025-11-28 |
| SG11202102479TA (en) | 2021-04-29 |
| AU2019339488B2 (en) | 2025-07-10 |
| BR112021004550A2 (pt) | 2021-06-08 |
| AU2019339488A1 (en) | 2021-04-08 |
| EP3849540A1 (en) | 2021-07-21 |
| JP2025138639A (ja) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| CO2021000151A2 (es) | Inhibidores de pd-1/pd-l1 | |
| CL2019002895A1 (es) | Inhibidores de pd-1/pd-l1. | |
| MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
| CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
| CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| BR112018073329A2 (pt) | combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase | |
| MX378386B (es) | Composiciones antiirritantes sinérgicas de taurina y aloe. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| MX2018010191A (es) | Inhibidores de glucosidasa. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
| PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
| CL2009000625A1 (es) | Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo. | |
| MX2021002994A (es) | Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1). | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. |